Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents (Q34707930)

4 August 2017

1 reference

title

Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents (English)

1 reference

4 August 2017

Vern L Schramm

1

1 reference

PubMed ID

12084452

4 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

Biochimica et Biophysica Acta

4 August 2017

1 reference

4 August 2017

1587

1 reference

4 August 2017

2-3

1 reference

4 August 2017

107-117

1 reference

Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleoside substrates

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s)

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: Genetic model for immunodeficiency disease

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Structure-based design of inhibitors of purine nucleoside phosphorylase. 3. 9-Arylmethyl derivatives of 9-deazaguanine substituted on the methylene group

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Structure-based design of inhibitors of purine nucleoside phosphorylase. 4. A study of phosphate mimics

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

The use of isotope effects to determine transition-state structure for enzymic reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Steady-state analysis of kinetic isotope effects in enzymic reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Enzymatic transition states and transition state analog design

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Transition State Analogues for Enzyme Catalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Purine nucleoside phosphorylase. Inosine hydrolysis, tight binding of the hypoxanthine intermediate, and third-the-sites reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Purine nucleoside phosphorylase. Catalytic mechanism and transition-state analysis of the arsenolysis reaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Pre-steady-state transition-state analysis of the hydrolytic reaction catalyzed by purine nucleoside phosphorylase.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Reduction of Ribonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

T-cell apoptosis detected in situ during positive and negative selection in the thymus

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Genetic deficiency of purine nucleoside phosphorylase in the mouse. Characterization of partially and severely enzyme deficient mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Point mutations at the purine nucleoside phosphorylase locus impair thymocyte differentiation in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

The ATP synthase--a splendid molecular machine

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Enzymatic transition-state analysis and transition-state analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Determining transition states from kinetic isotope effects

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Computational methods for transition state and inhibitor recognition.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Transition-state analysis of nucleoside hydrolase from Crithidia fasciculata

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Transition-state structures for N-glycoside hydrolysis of AMP by acid and by AMP nucleosidase in the presence and absence of allosteric activator.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Correlation of the molecular electrostatic potential surface of an enzymatic transition state with novel transition-state inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Prediction of inhibitor binding free energies by quantum neural networks. Nucleoside analogues binding to trypanosomal nucleoside hydrolase.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Synthesis of Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase and N-Riboside Hydrolases

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Addition of lithiated 9-deazapurine derivatives to a carbohydrate cyclic imine: convergent synthesis of the aza-C-nucleoside immucillins.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Calf spleen purine nucleoside phosphorylase complexed with substrates and substrate analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Purine nucleoside phosphorylase from Mycobacterium tuberculosis. Analysis of inhibition by a transition-state analogue and dissection by parts

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Transition state analogue inhibitors of purine nucleoside phosphorylase from Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Structures of purine nucleoside phosphorylase from Mycobacterium tuberculosis in complexes with immucillin-H and its pieces

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Purine-less death in Plasmodium falciparum induced by immucillin-H, a transition state analogue of purine nucleoside phosphorylase

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Transition state structure of purine nucleoside phosphorylase and principles of atomic motion in enzymatic catalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Atomic motion in enzymatic reaction coordinates

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

The metabolism of deoxyguanosine and guanosine in human B and T lymphoblasts. A role for deoxyguanosine kinase activity in the selective T-cell defect associated with purine nucleoside phosphorylase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

Transfer of a functional human immune system to mice with severe combined immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900073-X

7 January 2021

10.1016/S0925-4439(02)00073-X

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12084452